News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Tower Semiconductor signed $1.3 billion in silicon photonics contracts for 2027 and secured $290 million in prepayments to fund capacity expansion.
  • Wolfspeed shares jumped 20% after a thematic research firm named it an AI-infrastructure standout, extending a multi-day semiconductor rally.
  • Nvidia CEO Jensen Huang joined President Trump on a trip to China, boosting sentiment for AI-infrastructure suppliers.
  • Gilat reported Q1 revenue rose 20% to $110.5 million and delivered GAAP operating income, reaffirming 2026 growth and EBITDA guidance.
  • Vishay posted Q1 revenue of $839.2 million with a strong 1.34 book-to-bill and reaffirmed higher Q2 revenue and margin guidance.
  • Quaest poll shows Lula 42% and Flavio Bolsonaro 41% in a simulated runoff, signaling a tight October presidential race.
  • J.P. Morgan downgraded Heineken to neutral citing leadership uncertainty, flagging potential slowdown in momentum into Q2.

Latest Articles

Dentsply Sirona Expands U.S. Distribution Footprint Through Enhanced Agreement with Atlanta Dental Supply

Dentsply Sirona Expands U.S. Distribution Footprint Through Enhanced Agreement with Atlanta Dental Supply

Dentsply Sirona has announced an enhanced distribution agreement with Atlanta Dental Supply, enabling the latter to offer Dentsply Sirona's digital dentistry technologies in the U.S. from August 1. This strategic move strengthens Dentsply Sirona's market presence in the Southeast and supports its focus on expanding digital dentistry offerings throu…

Strategy Inc Director Executes Share Sales Totalling $676,700

Strategy Inc Director Executes Share Sales Totalling $676,700

Jarrod M Patten, a director at Strategy Inc (NASDAQ:MSTR), recently completed transactions involving the sale of 3,900 shares of Class A Common Stock. The sales occurred over a two-day period in late April and early May 2026, following the exercise of stock options that allowed for the acquisition of 4,000 shares at a significantly lower price poin…

Alexandria Real Estate Executive Increases Stake Amid Market Volatility

Alexandria Real Estate Executive Increases Stake Amid Market Volatility

Thomas Gregory Calvin, who serves as the Executive Vice President and Chief Technology Officer at Alexandria Real Estate Equities, Inc. (NASDAQ: ARE), has executed a notable purchase of company shares. On April 30, 2026, Calvin acquired 3,500 shares of common stock at a price point of $41.0 per share. This transaction represents a total investment …

Pool Corporation Announces Leadership Transition

Pool Corporation Announces Leadership Transition

Pool Corporation has appointed John B. Watwood as its new President and CEO, effective May 4, 2026, succeeding Peter D. Arvan who is stepping down from his roles. John E. Stokely transitions to Executive Chair. The company remains on track with its full-year 2026 financial guidance and postpones its Investor Day event to a later date.

Microvast Schedules First Quarter Earnings Call

Microvast Schedules First Quarter Earnings Call

Microvast Holdings, Inc., a leading developer of advanced battery technologies for electric vehicles and energy storage, announced it will release its Q1 2026 financial results after market close on May 11, 2026. A webcast and earnings call will follow to discuss business results and outlook. The company highlighted its 19-year legacy and extensive…

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

Opus Genetics announced that its investigational gene therapy OPGx-LCA5 for Leber congenital amaurosis type 5 (LCA5), a rare inherited retinal disease, has been accepted into the FDA's Rare Disease Evidence Principles (RDEP) program. This acceptance supports collaboration with the FDA on regulatory strategy and clinical trial design, potentially ac…

Unitil Reports 2026 First Quarter Earnings

Unitil Reports 2026 First Quarter Earnings

Unitil Corporation announced a net income of $33.2 million, or $1.85 EPS, for Q1 2026, reflecting a $5.7 million increase from Q1 2025. Adjusted net income, excluding transaction costs related to recent acquisitions, was $33.8 million or $1.88 EPS. The company experienced higher electric and gas gross margins driven by rate increases, customer grow…